X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1663) 1663
Publication (333) 333
Book Review (26) 26
Book / eBook (8) 8
Book Chapter (3) 3
Conference Proceeding (3) 3
Data Set (3) 3
Web Resource (3) 3
Magazine Article (2) 2
Government Document (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1503) 1503
hiv infections - drug therapy (1025) 1025
index medicus (1019) 1019
anti-retroviral agents - therapeutic use (874) 874
anti-retroviral agents - pharmacology (751) 751
female (701) 701
male (700) 700
hiv (656) 656
adult (612) 612
infectious diseases (557) 557
pharmacology & pharmacy (548) 548
middle aged (442) 442
antiviral agents (403) 403
antiretroviral therapy (400) 400
hiv infections - virology (352) 352
immunology (330) 330
hiv-1 - drug effects (298) 298
virology (280) 280
human immunodeficiency virus--hiv (267) 267
aids (266) 266
highly active antiretroviral therapy (263) 263
microbiology (262) 262
hiv infection (256) 256
viral load (255) 255
anti-retroviral agents - administration & dosage (251) 251
animals (233) 233
therapy (231) 231
antiretroviral drugs (225) 225
drug therapy (222) 222
anti-retroviral agents - adverse effects (214) 214
human-immunodeficiency-virus (214) 214
hiv-1 - genetics (207) 207
drug resistance, viral (205) 205
treatment outcome (202) 202
health aspects (185) 185
hiv infections - epidemiology (174) 174
research (174) 174
article (170) 170
human immunodeficiency virus (168) 168
analysis (167) 167
infection (167) 167
hiv infections - complications (157) 157
hiv infections - immunology (155) 155
risk factors (155) 155
hiv-1 (154) 154
cd4 lymphocyte count (152) 152
prevalence (152) 152
anti-retroviral agents - pharmacokinetics (150) 150
drug interactions (149) 149
acquired immune deficiency syndrome--aids (148) 148
protease inhibitors (147) 147
young adult (147) 147
adolescent (146) 146
drug resistance (145) 145
antiretroviral agents (144) 144
medicine (138) 138
research article (138) 138
cohort studies (133) 133
mutation (129) 129
aged (125) 125
antiretroviral therapy, highly active (120) 120
drug therapy, combination (120) 120
genotype (120) 120
pharmacokinetics (117) 117
virus diseases (117) 117
hiv infections - transmission (116) 116
hiv-1 - isolation & purification (113) 113
retrospective studies (113) 113
care and treatment (112) 112
pharmacology (111) 111
infections (109) 109
drugs (108) 108
antiretrovirals (105) 105
immunodeficiency-virus type-1 (105) 105
time factors (104) 104
acquired immune deficiency syndrome (103) 103
mortality (99) 99
cross-sectional studies (98) 98
hiv - drug effects (96) 96
dosage and administration (95) 95
tenofovir (93) 93
viruses (93) 93
drug resistance, viral - genetics (91) 91
child (90) 90
science (90) 90
hiv patients (89) 89
hiv-infected patients (89) 89
infected patients (89) 89
reverse-transcriptase inhibitors (89) 89
aids/hiv (88) 88
hiv infections - prevention & control (88) 88
active antiretroviral therapy (87) 87
multidisciplinary sciences (87) 87
patients (87) 87
hiv/aids (85) 85
pregnancy (84) 84
prospective studies (84) 84
prevention (82) 82
mutations (81) 81
treatment failure (78) 78
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1601) 1601
Spanish (44) 44
French (10) 10
German (9) 9
Portuguese (6) 6
Japanese (4) 4
Russian (4) 4
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2010, Volume 87, Issue 3, pp. 322 - 329
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2013, Volume 110, Issue 41, pp. 16538 - 16543
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 08/2013, Volume 63, Issue 4, pp. 449 - 455
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 06/2018, Volume 62, Issue 6, p. e00029-18
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2011, Volume 150, Issue 2, pp. 204 - 211
Long-term antiretroviral therapy (ART) for human immunodeficiency virus type one (HIV-1) infection shows limitations in pharmacokinetics and biodistribution... 
Nanoparticles | HIV | Monocyte | Crystalline | Antiretroviral | Nanomedicine | Macrophage | CELLS | HUMAN-IMMUNODEFICIENCY-VIRUS | CHEMISTRY, MULTIDISCIPLINARY | ANTI-HIV DRUGS | ADHERENCE | DELIVERY | PHYSICOCHEMICAL PROPERTIES | THERAPY | PHARMACOKINETICS | WATER-SOLUBLE DRUGS | PHARMACOLOGY & PHARMACY | Indinavir - administration & dosage | Nanoparticles - chemistry | Humans | Benzoxazines - metabolism | Indinavir - pharmacology | Microbial Sensitivity Tests | Macrophages - virology | Atazanavir Sulfate | Ritonavir - pharmacology | Indinavir - metabolism | Microscopy, Electron, Transmission | Virus Replication - drug effects | Microscopy, Electron, Scanning | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Anti-Retroviral Agents - pharmacology | Oligopeptides - metabolism | Static Electricity | Anti-Retroviral Agents - metabolism | Particle Size | Macrophages - metabolism | Pyridines - metabolism | Ritonavir - metabolism | Anti-Retroviral Agents - administration & dosage | Benzoxazines - pharmacology | Macrophages - drug effects | Oligopeptides - administration & dosage | Pyridines - pharmacology | Surface-Active Agents - chemistry | Oligopeptides - pharmacology | Highly active antiretroviral therapy | Antiviral agents | Macrophages | Analysis | Particle size | Surface charge | Ritonavir | antiretroviral therapy | Cytotoxicity | Drug delivery | Coatings | Surfactants | Efavirenz | Infection | Monocytes | nanoparticles | Physical characteristics | Antiviral activity | Replication | Pharmacokinetics | Controlled release | Indinavir | antiretroviral | crystalline | macrophage | monocyte | nanomedicine
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2017, Volume 56, Issue 1, pp. 25 - 40
Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the latest class of antiretrovirals (ARVs) that have become available to treat... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | TWICE-DAILY RALTEGRAVIR | ONCE-DAILY DOLUTEGRAVIR | SERONEGATIVE SUBJECTS | TREATMENT-EXPERIENCED PATIENTS | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS | RANDOMIZED CONTROLLED-TRIAL | ANTIRETROVIRAL-NAIVE ADULTS | HIV Integrase Inhibitors - pharmacology | Coinfection | Area Under Curve | Humans | Raltegravir Potassium - therapeutic use | Half-Life | Metabolic Clearance Rate | HIV Integrase - metabolism | HIV Integrase Inhibitors - administration & dosage | Liver Failure - metabolism | Drug Interactions | Quinolones - pharmacokinetics | Quinolones - therapeutic use | Female | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Anti-Retroviral Agents - therapeutic use | Raltegravir Potassium - pharmacokinetics | Anti-Retroviral Agents - pharmacokinetics | Anti-Retroviral Agents - pharmacology | HIV Integrase Inhibitors - pharmacokinetics | Renal Insufficiency - metabolism | Pregnancy | Cytochrome P-450 CYP3A - metabolism | Anti-Retroviral Agents - administration & dosage | Heterocyclic Compounds, 3-Ring - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Protein Binding | HIV Infections - drug therapy | Drug Combinations | Antiviral agents | Usage | Care and treatment | Pharmacology | Research | Diagnosis | Pharmacokinetics | Comparative analysis | HIV infection | Cytochrome | Antiretroviral drugs | Enzymes | Infections | Glycoproteins | Metabolism | Patients | Studies | Proteins | Human immunodeficiency virus--HIV | Adults | Drug dosages | Volunteers
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 512, Issue 1, pp. 74 - 77
The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1) eradication strategies(1-5). However, it remains unclear... 
LATENT INFECTION | REPLICATION | INITIATION | MULTIDISCIPLINARY SCIENCES | ACTIVE ANTIRETROVIRAL THERAPY | VACCINE | PREVENTION | DYNAMICS | IMMUNODEFICIENCY VIRUS-INFECTION | DEPENDS | HIV-1 INFECTION | DNA, Viral - biosynthesis | Macaca mulatta - immunology | Simian Immunodeficiency Virus - growth & development | DNA, Viral - analysis | Male | RNA, Viral - blood | Rectum - virology | Macaca mulatta - virology | Simian Acquired Immunodeficiency Syndrome - virology | Proviruses - genetics | Time Factors | Treatment Failure | Female | Disease Models, Animal | Simian Immunodeficiency Virus - immunology | Virus Replication - drug effects | Anti-Retroviral Agents - therapeutic use | Anti-Retroviral Agents - pharmacology | Viremia - drug therapy | Simian Immunodeficiency Virus - physiology | DNA, Viral - blood | Carrier State - virology | Animals | Simian Acquired Immunodeficiency Syndrome - drug therapy | Simian Acquired Immunodeficiency Syndrome - immunology | Viremia - virology | Anti-Retroviral Agents - administration & dosage | Carrier State - drug therapy | Kinetics | Viral Load - drug effects | Simian Immunodeficiency Virus - drug effects | Physiological aspects | Simian immunodeficiency virus | Virulence (Microbiology) | Studies | Antiretroviral drugs | Lymphocytes | Human immunodeficiency virus--HIV | Infections | Monkeys & apes | Deoxyribonucleic acid--DNA
Journal Article